MgShell aims to revolutionize the therapeutic approach in the ophthalmological field. The company goal arises from the need to solve the issues associated to patients suffering from maculopathy. The number of affected people increases dramatically (500’000 yearly new diagnosis, 300 million patients at 2040), and the therapeutic adherence is so low that 40% of patients do not follow the correct strategy and go blind. MgShell proposes i3D, a biodegradable intraocular drug-delivery device able to replicate the current clinical practice without surgery, drastically increasing the patient compliance, decreasing healthcare costs and generating business for pharmaceutical companies.